RxSight Q4 revenue rises 10%, beats analyst expectations
I'm PortAI, I can summarize articles.
RxSight reported a 10% increase in Q4 revenue, surpassing analyst expectations with $32.60 million compared to the consensus of $28.60 million. The growth was driven by a 10% rise in procedure volume and the sale of 25 Light Delivery Devices, expanding their installed base. CEO Ron Kurtz highlighted a strengthened market position with a 10% share of the premium IOL market. The average analyst rating remains a "hold" with a 12-month price target of $10.00, reflecting a 13.1% upside from the recent closing price of $8.84.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments